Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Vera Therapeutics ( (VERA) ) is now available.
On December 16, 2025, Vera Therapeutics, Inc. announced that Jason Carter will step down from his role as Chief Legal Officer, effective December 24, 2025. The leadership change removes a key executive from the company’s legal function and may signal an upcoming transition or reorganization within its senior management team.
The most recent analyst rating on (VERA) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Average Trading Volume: 1,608,245
Technical Sentiment Signal: Buy
Current Market Cap: $3.38B
For a thorough assessment of VERA stock, go to TipRanks’ Stock Analysis page.